Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 17, 2025 11:45 ET | Source: XOMA Royalty Corporation; LAVA Therapeutics N.V.

XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement

- Amendment includes finalized cash amount and updated CVR terms for tender offer - LAVA announces new date for extraordinary general meeting of shareholders EMERYVILLE, Calif. and UTRECHT, The...
October 02, 2025 16:43 ET | Source: XOMA Royalty Corporation; LAVA Therapeutics

XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.

XOMA Royalty extends its tender offer for LAVA Therapeutics.
September 22, 2025 07:30 ET | Source: XOMA Royalty Corporation

XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMA Royalty announces October 2025 dividend
September 17, 2025 09:00 ET | Source: XOMA Royalty Corporation

XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.

XOMA Royalty closes tender offer for HilleVax.
September 03, 2025 07:30 ET | Source: XOMA Royalty Corporation

XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference

EMERYVILLE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief...
August 20, 2025 08:49 ET | Source: XOMA Royalty Corporation

Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

WALTHAM, Mass. and DUBLIN and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company (“Mural”), and XOMA Royalty...
August 13, 2025 07:30 ET | Source: XOMA Royalty Corporation

XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

Business development: Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA...
August 11, 2025 09:00 ET | Source: XOMA Royalty Corporation

XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics

XOMA Royalty closes tender offer for Turnstone Biologics.
August 04, 2025 07:30 ET | Source: XOMA Royalty Corporation; LAVA Therapeutics N.V.

XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right

XOMA Royalty to Acquire LAVA for between $1.16 and $1.24 per share in cash plus a CVR.
August 04, 2025 07:00 ET | Source: XOMA Royalty Corporation

HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right

BOSTON and EMERYVILLE, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (“HilleVax” or “the Company”) (NASDAQ: HLVX) and XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) announced...